Prothena Corp. plc, of Dublin, reported results from a phase Ib multiple ascending dose trial testing PRX003 in 33 patients with psoriasis. PRX003, a monoclonal antibody targeting CD146 that's expressed on T helper 17 cells (Th17), didn't produce meaningful clinical benefit as measured by responses in the Psoriasis Area and Severity Index 75.